STOCK TITAN

Liminal Biosciences Inc - LMNL STOCK NEWS

Welcome to our dedicated news page for Liminal Biosciences (Ticker: LMNL), a resource for investors and traders seeking the latest updates and insights on Liminal Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Liminal Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Liminal Biosciences's position in the market.

Rhea-AI Summary
Liminal BioSciences Inc. has completed a transaction with Structured Alpha LP, where SALP acquired all outstanding common shares of Liminal BioSciences at a price of US$8.50 per share. As a result, the shares will no longer be listed on the Nasdaq Capital Market, and Liminal BioSciences will cease to be a reporting issuer under Canadian securities law. The company is focused on developing small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Liminal BioSciences received final court order for plan of arrangement with Structured Alpha LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Liminal BioSciences shareholders approve plan of arrangement with Structured Alpha LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary
Liminal BioSciences files amended Schedule 13E-3 and supplement to the management information circular
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Liminal BioSciences Inc. has obtained an interim order from the Ontario Superior Court of Justice for a proposed arrangement with Structured Alpha LP. Under the arrangement, SALP will acquire all outstanding common shares of Liminal BioSciences not currently owned by SALP or its affiliates at a price of US$8.50 per share. The arrangement is subject to shareholder approval and the issuance of a final court order.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Liminal BioSciences Inc. (Nasdaq: LMNL) provided an R&D update on their GPCR-targeted pipeline, including the nomination of a lead candidate for the OXER1 antagonist program. They also reported their financial results for the second quarter ended June 30, 2023, with a net loss from continuing operations of CAD 9 million. The company closed June 30, 2023, with over CAD 19 million cash on hand, expecting to provide cash runway into December 2023. Additionally, they entered into an Arrangement Agreement with Structured Alpha LP, potentially providing minority shareholders US$8.50 in cash per Common Share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
earnings
Rhea-AI Summary
Liminal BioSciences Inc. and Structured Alpha LP have entered into an agreement under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences. Liminal BioSciences shareholders will receive US$8.50 in cash per share, representing a premium of approximately 135% over the closing share price on Nasdaq on April 4, 2023. The transaction is expected to close no later than September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
earnings
Liminal Biosciences Inc

Nasdaq:LMNL

LMNL Rankings

LMNL Stock Data

27.62M
1.26M
61.26%
0.77%
0.02%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Canada
Laval

About LMNL

liminal biosciences inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. it operates through two segments, small molecule therapeutics and plasma derived therapeutics. the small molecule therapeutics segment's lead product candidate is fezagepras (pbi-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and alstrã¶m syndrome. the plasma derived therapeutics segment provides plasma protein purification system, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. it also engages in developing ryplazim for the treatment of congenital plasminogen deficiency. the company operates in canada, the united kingdom, and the united states. the company was formerly known as prometic life sciences inc. and changed its name to liminal biosciences inc. in october